Clovis Oncology (CLVS) Misses Q4 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Clovis Oncology Announces 2020 Operating Results
February 23, 2021 8:00 AM EST$164.5M in Rubraca® (rucaparib) global net product revenues for 2020, up 15% over 2019; $43.3M in Rubraca global net product revenues for Q4 2020, up 10% over Q4 2019 Phase 1/2 LuMIERE study of FAP-2286, a targeted radiotherapy, planned to begin 1H 2021 Top-line data from Phase 3 ATHENA trial of Rubraca as first-line maintenance ovarian cancer monotherapy anticipated 2H 2021 Interim data from Phase 2 cohorts of LIO-1 study of lucitanib in combination with Opdivo® (nivolumab) in gynecologic cancers anticipated at 2021 medical meetings Net cash used in operating activities significantly lower in 2020 compared to... More
